Marpai, Inc. · OTC:MRAI
Marpai — Investor Presentation (November 2021)
24 slides from Marpai's investor presentation, Nov 10, 2021
Slide 1: fad
< (al, fad
Slide 2: Forward Looking Statements
Fonvard Looking Statements ‘The Company fled a registration statement on Form S-1, as amended (Registration No.: 333-258029) (he “Registration Statement) with the Secures and Exchange Commission for fs intial public offering of shares of class A common stock which was declared effective on October 2
Slide 3: Who We Are
Who We Are a —_- . 7 Mission bet Save lives, improve lives, Ss radically reduce healthcare spending
Slide 4: Transforming a $1+ Trillion Segment of Healthcare Industry with Deep Learning
Transforming a $1+ Trillion Segment of Healthcare Industry with Deep Learning Transformi g Self-Insured Health Plans MARPAI Creating Healthier Lives Radically Reducing Healthcare Costs Goals PREDICTIVE paar PF auality care PB Preventative Care EFFICIENT § Fear & Complexity MAR PALL sources: McLean C
Slide 5: Employer Sponsored Health Plans
Employer Sponsored Health Plans 49% ot americans receive employer J ‘sponsoredihealth insurance 2 "57MM people? Our Market: Self-Funded Employers Paying $20+ Billion in Third Party Administration Fees‘ ‘Fully Insured =, -—‘Self Funded Health Plan Health Plan Pay insurance company to Pay health costs
Slide 6: Solid Foundation to Scale
Solid Foundation to Scale World-Class L1™ 6/30/21 Covering Networks Revenue: $16.2M including Unit Economics: aetna $63 PEPM Af. Cigna Strong Short list of Pipeline for M&A targets 2021 and (buying books beyond of business) VOLUMES: 534k+ Claims Processed $620M Filed Claims TOTAL SAVINGS: $418M MARP
Slide 7: Tech Brings Revolutionizing Alternative
Tech Brings Revolutionizing Alternative OLD WORLD PAYERS: ESTABLISHED BUCA’s eo TECH-FIRST PAYERS Pay A Lot $$$ oes. MARDAT No Transparency No Control S@.cigna ® CENTIVO" © bind aetna Bright HealthGroup’ Colective Collectve OSCAr Lower Costs Simple, Responsive, Personalized High Automation Pay Less
Slide 8: Types of Artificial Intelligence
Types of Artificial Intelligence RPAI
Slide 9: Machine Learning vs. Deep Learning
Machine Learning vs. Deep Learning Deep Learning Barriers of Entry Vector of features Machine Learning Raw Data Deep Learning Greatest leap in accuracy in the history of Al, due to deep learning. MARPAI Is
Slide 10: Marpai AI
Marpai Al Applications Present & Future Data Sources RPAI Conditions Medical Claims Rx Claims SDOH Member Preferences, Pre High Cost Surgeries and Imaging - Recommendations Provider Quality Wearable Devices Ratings loT Devices Network Data EHR Images Lab Results Provider Schedules
Slide 11: Investment Opportunity
Investment Opportunity High Margin High Revenue Growth Tech-driven cost reduction Superior product offering Predict, Prevent and Protect Highly Differentiated Goal: reduce cost to 1/3 of industry ‘Organic + Acquisitions Higher Al- enabled quality care MOAT PROPRIETARY ALGORITHMS TECHPLATFORM INNOVAT
Slide 12: Our Products
Our Products 3 SMART Plan _ Manage and Pay Claims Efficiently Administration Automation of Processes + Elimination of Errors FutureSight Predict, Prevent, Protect Proprietary Advantage Early Detection + Intervention = Best Care Algorithms Match Members with Top Providers TopCare Recommends top 10% o
Slide 13: SMART Plan Administration
Se SMART Plan Administration Making Marpai an efficient TPA Key Features for Acquisitions + Creates efficiencies Eliminates abuse, cost excesses, errors Accelerates workflows » Provides 24/7 responsive service Collects data to yield new insights Automated 2/3 of system queues Reduced staff of acquir
Slide 14: FutureSight Advantage
& Ps FutureSight Advantage Predicts, Prevents, Protects MARPAI PROPRIETARY ALGORITHMS | tw | 50 Tota highest cost areas Chronic conditions + Diabetes Type 2 + Hypertension + Cardiovascular + Hyperlipidemia Disease * IHD Kidney Disease + Heart Failure Chronic and mental health conditions are COPD + A
Slide 15: Marpai TopCare
a (> Marpai TopCare aa Drives Members to High sa Cost Care Additional Stop Loss Discount 5%-10% MARPAI
Slide 16: Variation in Cost of Common Procedures
Variation in Cost of Common Procedures We believe that Al-enabled prediction allows us to guide members to the best care in terms of cost and quality Distribution of Claims for MRI of the Brain (cer 70553) baes Distribution of Claims for CT of the Thorax (with contrast) (cPT 71260) MARPAL hk Source:
Slide 17: Proactive Engagement
Proactive Friendly nudges, alerts, reminders, content, incentives v MARPAI Engagement To empower members to do the right things at the right times with the most qualified providers
Slide 18: Expansion of Unit Economics
Expansion of Unit Economics We plan for the expansion of per employee per month fee (PEPM) to be potentially driven by Al and related new services Marpai 6/30/2021 PEPM ata a) + Increased revenue share vi program (e.g. care mana MARPAI 118
Slide 19: Drivers of Growth
Drivers of Growth We believe that Marpai's deep learning platform has the potential to serve as the foundation for the company to become a disruptive consolidator in the self-funded health plan space Organic Drivers Acquisition Drivers Better products, powered by Al 2 ential targets for roll-up stra
Slide 20: Capitalization
Capitalization Common Shares Outstanding Warrants ($5.83 WAEP) Options ($1.77 WAEP) 19,185,396 1,561,373 1,503,421 Fully Diluted Shares 22,250,190
Slide 21: Public Comps
Public Comps Enterprise TTM Enterprise Value Name Ticker Value (M)' Revenue (M) __/Revenue Description ‘Accolade, Ine. ‘ACCD $2548 $230" 11.1x Tech and Alfocused; member management, care managernent and elhealh for employers Health Catalyst, Inc. HCAT $2,568 $216 11.9% Tech and Afocuso big data for
Slide 22: Who We Are
Who We Are Seasoned Board of Leadership Team Directors Me co one ‘Chairman Gonzalez ‘C00 President of ele CEO ‘Marpai Labs pallial y jee arts ).... oue = ) a, 4) ee) OM C et Sate havior Gonen Antebi Colleen Diclaudio Jane Cavalier Vincent Kane Director Nominee Director Nominee Director Nominee Direc
Slide 23: Investment Summary
MARPAI a Investment Summary $20+ Billion Market Opportunity Highly differentiated Al products Tech-Driven Strategy with Advanced Al Growth Model is Working : +20% New Lives Implemented 9/1 Highly Efficient Payer Predict Health States Organic + Acquisitions Prevent Illness > >> Claims | High Costs Ma
Slide 24: Thank you